ZYBT (Zhengye Biotechnology Holding) Marketable Securities: $0.22 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZYBT Zhengye Biotechnology Holding Ltd ZYBT
20 GF Score
Price $1.98
! 5 Warning Signs
View Full Analysis

What is Zhengye Biotechnology Holding Marketable Securities?

Zhengye Biotechnology Holding ZYBT +1.54% 20 Marketable Securities is $0.22 Mil as of Dec. 2025. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Zhengye Biotechnology Holding's Marketable Securities for the quarter that ended in Dec. 2025 was $0.22 Mil.

Zhengye Biotechnology Holding's annual Marketable Securities increased from Dec. 2023 ($0.17 Mil) to Dec. 2024 ($0.20 Mil) and increased from Dec. 2024 ($0.20 Mil) to Dec. 2025 ($0.22 Mil).

Zhengye Biotechnology Holding  (NAS:ZYBT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Zhengye Biotechnology Holding Marketable Securities Related Terms

Zhengye Biotechnology Holding Marketable Securities Historical Data

* Premium members only.

The historical data trend for Zhengye Biotechnology Holding's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhengye Biotechnology Holding Marketable Securities Chart

Zhengye Biotechnology Holding Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 0.00 0.17 0.20 0.22

Zhengye Biotechnology Holding Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Marketable Securities Get a 7-Day Free Trial Premium Member Only 0.17 0.18 0.20 0.28 0.22
ZYBT
20GF Score
Zhengye Biotechnology Holding Ltd ZYBT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhengye Biotechnology Holding Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.22 Mil mean?
Zhengye Biotechnology Holding (ZYBT) has a Marketable Securities of $0.22 Mil as of Dec. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Zhengye Biotechnology Holding and its competitors.
Is Zhengye Biotechnology Holding's Marketable Securities too high?
Zhengye Biotechnology Holding's current Marketable Securities is $0.22 Mil. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's Marketable Securities compare to TLPH and CPHI?
Zhengye Biotechnology Holding's Marketable Securities of $0.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Zhengye Biotechnology Holding and its competitors. Zhengye Biotechnology Holding's current Marketable Securities is $0.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current Marketable Securities of $0.22 Mil. The current Marketable Securities is $0.22 Mil. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current Marketable Securities is $0.22 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhengye Biotechnology Holding Business Description

Address No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, Jilin City, CHN
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score

Get the complete analysis for ZYBT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.98
Price